Anti-EJ antibody-positive interstitial pneumonia with breast cancer improved by combining immunosuppressive therapy and chemotherapy

Ai Koike,Masako Arimura-Omori,Shuyo Umeda,Akihisa Takano,Yasuyuki Kishikawa,Satoshi Nakamura,Yuriko Takahata,Yuki Okamatsu,Akitaka Fujita,Taishi Harada
DOI: https://doi.org/10.1016/j.rmcr.2023.101950
2023-11-27
Abstract:We present a case of a 45-year-old woman diagnosed with interstitial pneumonia (IP) during a comprehensive breast cancer evaluation. Although the patient showed no obvious clinical symptoms of polymyositis or dermatomyositis, the presence of anti-glycyl-transfer ribonucleic acid synthetase antibodies confirmed anti-synthetase syndrome. The patient began methylprednisolone for treatment of the IP. She then received preoperative chemotherapy with epirubicin and cyclophosphamide before undergoing a mastectomy. A significant improvement was seen in the patient's IP during treatment. This case emphasizes the potential advantages of personalized immunosuppressive therapy for patients who are simultaneously diagnosed with anti-synthetase syndrome and cancer.
What problem does this paper attempt to address?